February 14, 2024 03:03 PM ESTUpdated 03:17 PM

Appeals court sides with AstraZeneca, BMS, McKesson in saxagliptin heart failure case

Nicole DeFeudis

Editor

A Sixth Circuit appeals court this week upheld a decision in favor of AstraZeneca, Bristol Myers Squibb and McKesson in a case alleging that diabetes …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Appeals court sides with AstraZeneca, BMS, McKesson in saxagliptin heart failure case

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Post-Hoc: Big promises built Moderna. They might also be its undoing

Bristol Myers touts LAG-3 strategy in lung cancer as it preps for showdown with Merck’s Keytruda

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

FDA approves subcutaneous Ocrevus, broadening access to Roche and Genentech blockbuster

House passes Biosecure Act, sending Chinese biotech ban to Senate

Ap­peals court sides with As­traZeneca, BMS, McKesson in saxagliptin heart fail­ure case

Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Appeals court sides with AstraZeneca, BMS, McKesson in saxagliptin heart failure case